semaglutide approved for mash Novo's Wegovy becomes first GLP-1 drug Novo Nordisk seeks approval for

Physician-guided care for appetite control, metabolic health, and long-term results.

The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.

This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes

Affordable GLP-1, Lipo, and HCG injections for safe, effective weight loss

Novo Nordisk has innovated a subcutaneous formulation of semaglutide, branded as Ozempic, which functions as a modified human glucagon-like peptide-1 (GLP-1) analogue

Learn about common and serious GLP-1 shot side effects, including nausea, fatigue, and digestive issuesplus tips to reduce discomfort safely.